Labcorp Holdings Cash and cash equivalents, end of period decreased by 11.0% to $532.30M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 65.0%, from $1.52B to $532.30M. Over 4 years (FY 2021 to FY 2025), Cash and cash equivalents, end of period shows a downward trend with a -22.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate strong liquidity and readiness to meet claims, whereas lower levels may signal a need for capital raising or asset liquidation.
This represents the total liquidity available to the company, including highly liquid assets and cash that may be subjec...
Insurance companies typically maintain high levels of cash and equivalents to satisfy regulatory liquidity requirements.
other_cash_cash_equivalents_restricted_cash_and_restrict_5675e1| Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.47B | $304.90M | $430.00M | $294.80M | $1.93B | $727.90M | $536.80M | $99.30M | $265.10M | $1.52B | $1.52B | $369.40M | $647.30M | $598.10M | $532.30M |
| QoQ Change | — | -79.3% | +41.0% | -31.4% | +554.9% | -62.3% | -26.3% | -81.5% | +167.0% | +472.4% | +0.1% | -75.7% | +75.2% | -7.6% | -11.0% |
| YoY Change | — | — | -70.8% | — | — | +138.7% | +24.8% | -66.3% | -86.3% | +108.4% | +182.9% | +272.0% | +144.2% | -60.6% | -65.0% |